Kalydeco® was approved by the FDA in 2012. Kalydeco® is an ion channel modulator for the treatment of cystic fibrosis (CF) in patients who have a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. These patients will have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, or R117H. Ion channel modulators aim to correct the cellular defect that causes CF rather than the severity of the symptoms caused by the disease. Kalydeco® is a tablet that is taken orally. Maxor has partnered with Vertex as a Limited Distribution Pharmacy for Kalydeco®.
Kalydeco® Guidance & Patient Support
Vertex GPS™ : Guidance & Patient Support is a program created by Vertex Pharmaceuticals to assist patients in the navigation of life with Cystic Fibrosis. Vertex GPS™ Case Managers are available to help provide information about reimbursement support, potential financial assistance, and disease and treatment information while a patient is on Kalydeco®.